The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Open accessAbstract
Amyloid plaques and neurofibrillary tangles (NFTs) are the pathological hallmarks of Alzheimer disease (AD). There is controversy regarding the use of current diagnostic criteria for AD and whether amyloid plaques and NFTs contribute to cognitive impairment. Because AD is specific to humans, rigorous and comprehensiveclinicopathologic studies are necessary to test and refine hypotheses of AD diagnosis and pathogenesis. Neither the clinical nor the pathological aspects of AD evolve in a linear manner, but thepredictable sequence of AD pathology allows for stage-based correlations with cognitive deterioration. We discuss subsets of patients with clinical dementia who lack amyloid plaques and NFTs and, conversely, whether individuals without antemortem cognitive impairment can harbor severe AD-type pathological findings at autopsy. There are many medical, technical, and anatomical challenges to clinicopathologic studies in AD. For example, at least two thirds of persons older than 80 years have non-AD brain diseases that can effect on cognitive function. We argue that existing data strongly support the hypothesis that both amyloid plaques and NFTs contribute to cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, AD is characterized by several features, notably a progressive cognitive decline involving loss of memory and higher executive functioning1.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
The cited source says what the claim attributes to it.
In the citing paper
“Evaluation of AD status was conducted by the AD Center Neuropathology and Clinical Cores using guidelines set forth by the National Institute on Aging Reagan Institute that included evaluation of neurofibrillary tangles and neuritic senile plaques [36–38].”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, the first pathological insults to neurons in AD and aMCI occur at pre- and post-synaptic membranes1,3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, this is precisely the observation reported by one of the largest autopsy series to date (142) and is well supported by AD biomarker studies (143-145).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is important to emphasize that, among thousands of cases from dozens of CPC studies worldwide, there never has been a report of a thoroughly documented individual with truly “end-stage” neocortical NFT pathology who lacked antemortem cognitive impairment proximal to death (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“However, not all Braak stage VI brains were the same; there was significant variation in NFT burden in these cases (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“There have been many clinicopathological studies that have correlated amyloid plaques with cognitive deficits in AD, with an emerging picture that the strongest correlation exists in the earliest stages of the disease and this association greatly weakens as NFTs and neocortical degeneration become more widespread [9, 102, 103, 157, 160, 169].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationLOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS
Scoville, W. B., & Milner, B. (1957) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.20.1.11 · Cited by 7,322
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Research works printed but not linked: 1
- Centers for Disease Control and Prevention. Prevalence of stroke-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–74
Cited by
Sorted by citations
Items 101–200 of 638
Bachstetter, A. D., Norris, C. M., Sompol, P. M., Wilcock, D. M., Goulding, D. S., Neltner, J. H., Clair, D. K. S., Watterson, D. M., & Eldik, L. J. V. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1496-12.2012 · Cited by 106
Hoekstra, J. G., Hipp, M. J., Montine, T. J., & Kennedy, S. R. (2016) · Annals of Neurology · doi:10.1002/ana.24709 · Cited by 108
Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress
Castellani, R. J., & Perry, G. L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.009 · Cited by 104
Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease
Tzen, K., Yang, S., Chen, T., Cheng, T.-W., Horng, H. E., Wen, H.-P., Huang, Y.-Y., Shiue, C., & Chiu, M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500101j · Cited by 105
Ondrejčák, T., Klyubin, I. V., Corbett, G. T., Fraser, G. M., Hong, W., Mably, A. J., Gardener, M. J., Hammersley, J., Perkinton, M. S., Billinton, A., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1700-18.2018 · Cited by 110
ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status
Vasquez, J. B., Fardo, D. W., & Estus, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.058 · Cited by 101
Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies
Nelson, P. T., Kryscio, R. J., Jicha, G. A., Abner, E. L., Schmitt, F. A., Xu, L. O., Cooper, G., Smith, C. D., & Markesbery, W. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bacf9e · Cited by 99
Self-citationon behalf of the MEMENTO cohort Study Group, Dufouil, C., Dubois, B., Vellas, B. J., Pasquier, F., Blanc, F., Hugon, J., Hanon, O., Dartigues, J., Harston, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0288-0 · Cited by 99
Latimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., Henriksen, J. C., Darvas, M., Domoto‐Reilly, K., Jayadev, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0743-1 · Cited by 102
Butterfield, D. A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101049 · Cited by 98
Significance of the so-called oval cell proliferation during azo-dye hepatocarcinogenesis.
Inaoka, Y. (1967) · PubMed · Cited by 97
Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition
Initiative, A. D. N., Tan, C. H., Fan, C. C., Mormino, E. C., Sugrue, L. P., Broce, I., Hess, C. P., Dillon, W. P., Bonham, L. W., Yokoyama, J. S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1789-4 · Cited by 95
Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease
Llanos-González, E., Henares-Chavarino, Á. A., Pedrero-Prieto, C. M., García‐Carpintero, S., Frontiñán-Rubio, J., Sancho-Bielsa, F. J., Alcain, F. J., Peinado, J. R., Rabanal‐Ruiz, Y., & Durán‐Prado, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01444 · Cited by 99
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113
Vision function abnormalities in Alzheimer disease
Tzekov, R., & Mullan, M. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.10.002 · Cited by 94
SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer’s disease
Younas, N., Zafar, S., Shafiq, M., Noor, A., Siegert, A., Arora, A. S., Galkin, A. P., Zafar, A., Schmitz, M., Stadelmann, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02178-y · Cited by 94
Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy
Chornenkyy, Y., Fardo, D. W., & Nelson, P. T. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0196-y · Cited by 93
Self-citationTremblay, C., St‐Amour, I., Schneider, J. A., Bennett, D. A., & Calon, F. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822c62cf · Cited by 98
Yu, N., Huang, Y., Jiang, Y., Zou, L., Liu, X., Liu, S., Chen, F., Luo, J., & Zhu, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9894037 · Cited by 97
Dopamine beta‐hydroxylase and its genetic variants in human health and disease
Gonzalez‐Lopez, E., & Vrana, K. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14893 · Cited by 91
Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease
LoBue, C., Wadsworth, H., Wilmoth, K., Clem, M., Hart, J., Womack, K. B., Didehbani, N., Lacritz, L. H., Rossetti, H. C., & Cullum, C. M. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1257069 · Cited by 90
Neuropathological approaches to cerebral aging and neuroplasticity
Jellinger, K. A., & Attems, J. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/kjellinger · Cited by 94
The complexities of the pathology–pathogenesis relationship in Alzheimer disease
Castellani, R. J., & Perry, G. L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.009 · Cited by 91
Lau, K. M., Parikh, M., Harvey, D. J., Huang, C.-J., & Farias, S. T. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000818 · Cited by 89
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Ye, X., Tai, W., & Zhang, D. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.004 · Cited by 90
Fornari, E., Maeder, P. P., Meuli, R. A., Ghika, J. A., & Knyazeva, M. G. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.014 · Cited by 88
Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging
van Rooden, S., Goos, J. D. C., van Opstal, A. M., Versluis, M. J., Webb, A. G., Blauw, G. J., van der Flier, W. M., Scheltens, P., Barkhof, F., van Buchem, M. A., et al. (2014) · Radiology · doi:10.1148/radiol.13130743 · Cited by 86
Pellicanò, M., Bulati, M., Buffa, S., Barbagallo, M., Di Prima, A., Misiano, G., Picone, P., Di Carlo, M., Nuzzo, D., Candore, G., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091714 · Cited by 86
Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
Boche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0705-y · Cited by 85
The Angiotensin II Type 2 Receptor in Brain Functions: An Update
Guimond, M., & Gallo‐Payet, N. (2012) · International Journal of Hypertension · doi:10.1155/2012/351758 · Cited by 84
Neltner, J. H., Abner, E. L., Schmitt, F. A., Denison, S. K., Anderson, S., Patel, E., & Nelson, P. T. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182768de4 · Cited by 85
Self-citationGenetics of CD33 in Alzheimer's disease and acute myeloid leukemia
Malik, M., Chiles, J. W., Xi, H. S., Medway, C., Simpson, J. F., Potluri, S., Howard, D. S., Yu, L., Paumi, C. M., Mukherjee, S., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv092 · Cited by 84
Circulating microRNAs in Alzheimer’s disease: the search for novel biomarkers
Dorval, V., Nelson, P. T., & Hébert, S. S. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00024 · Cited by 81
Self-citationDelgado‐Peraza, F., Nogueras‐Ortiz, C. J., Volpert, O. V., Liu, D., Goetzl, E. J., Mattson, M. P., Greig, N. H., Eitan, E., & Kapogiannis, D. (2021) · Cells · doi:10.3390/cells10050993 · Cited by 81
Hu, W., Zhang, Y., Wu, W., Yin, Y., Huang, D., Wang, Y., Li, W., & Li, W. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.09.019 · Cited by 83
Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
Saiz-Sanchez, D., De la Rosa-Prieto, C., Ubeda-Banon, I., & Martinez-Marcos, A. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0771-3 · Cited by 79
SantaCruz, K. S., Sonnen, J. A., Pezhouh, M. K., Desrosiers, M. F., Nelson, P. T., & Tyas, S. L. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822e8ae9 · Cited by 79
Self-citationMidlife predictors of Alzheimer's disease
Bendlin, B. B., Carlsson, C. M., Gleason, C. E., Johnson, S. C., Sodhi, A., Gallagher, C. L., Puglielli, L., Engelman, C. D., Ries, M. L., Xu, G., et al. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.12.014 · Cited by 81
Apostolova, L. G., Zarow, C., Biado, K., Hurtz, S., Boccardi, M., Somme, J. H., Honarpisheh, H., Blanken, A. E., Brook, J. K., Tung, S., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.01.001 · Cited by 77
Hill, E., Karikari, T. K., Moffat, K. G., Richardson, M. J. E., & Wall, M. J. (2019) · eNeuro · doi:10.1523/eneuro.0166-19.2019 · Cited by 83
Neuroanatomical Correlates of Cognitive Reserve in Alzheimer Disease
Serra, L., Cercignani, M., Petrosini, L., Basile, B., Perri, R., Fadda, L., Spanò, B., Marra, C., Giubilei, F., Carlesimo, G. A., et al. (2011) · Rejuvenation Research · doi:10.1089/rej.2010.1103 · Cited by 81
Tam, J. H. K., Seah, C., & Pasternak, S. (2014) · Molecular Brain · doi:10.1186/s13041-014-0054-1 · Cited by 83
Cui, M., Ono, M., Kimura, H., Liu, B., & Saji, H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101404k · Cited by 76
Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk
Ling, I., Bhongsatiern, J., Simpson, J. F., Fardo, D. W., & Estus, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033923 · Cited by 76
Minjarez, B. D., Calderón-González, K. G., Rustarazo, M. L. V., Herrera-Aguirre, M. E., Labra‐Barrios, M. L., Rincón-Limas, D. E., del Pino, M. M. S., Mena, R., & Luna‐Arias, J. P. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.03.022 · Cited by 75
Markus, R. P., Silva, C. L. M., Franco, D. G., Barbosa, E. M., & Ferreira, Z. S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.009 · Cited by 74
Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
Shade, L. M. P., Katsumata, Y., Abner, E. L., Aung, K. Z., Claas, S. A., Qiao, Q., Heberle, B. A., Brandon, J. A., Page, M. L., Hohman, T. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01939-9 · Cited by 72
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Self-citationA Chemical Analog of Curcumin as an Improved Inhibitor of Amyloid Abeta Oligomerization
Orlando, R. A., Gonzales, A. M., Royer, R. E., Deck, L. M., & Jagt, D. L. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031869 · Cited by 71
Jensen‐Dahm, C., Werner, M. U., Dahl, J. B., Jensen, T. S., Ballegaard, M., Hejl, A., & Waldemar, G. (2014) · Pain · doi:10.1016/j.pain.2013.12.031 · Cited by 70
Initiative, A. D. N., Roostaei, T., Nazeri, A., Felsky, D., Jager, P. L. D., Schneider, J. A., Pollock, B. G., Bennett, D. A., & Voineskos, A. N. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.35 · Cited by 71
Decourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
Sideris, D. I., Danial, J. S. H., Emin, D., Ruggeri, F. S., Xia, Z., Zhang, Y. P., Lobanova, E., Dakin, H., De, S., Miller, A., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab147 · Cited by 71
Visual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 74
Belsare, K. D., Wu, H., Mondal, D., Bond, A., Castillo, E., Jin, J., Jo, H., Roush, A. E., Pilla, K. B., Sali, A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114486119 · Cited by 68
Pathogenesis of Alzheimer’s Disease
Castellani, R. J., & Perry, G. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_162 · Cited by 67
Insights into lncRNAs in Alzheimer’s disease mechanisms
Li, D., Zhang, J., Li, X., Chen, Y., Feng, Y., & Liu, Q. (2020) · RNA Biology · doi:10.1080/15476286.2020.1788848 · Cited by 68
Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Fish, K. N., Ikonomović, M. D., Hamilton, R. L., Kofler, J., Klunk, W. E., López, O. L., & Sweet, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131166 · Cited by 67
Wang, Y., MacDonald, R. G., Thinakaran, G., & Kar, S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9849-7 · Cited by 68
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
Mormino, E. C., Toueg, T. N., Azevedo, E. C., Castillo, J. B., Guo, W., Nadiadwala, A., Corso, N. K., Hall, J. N., Fan, A. P., Trelle, A. N., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04923-7 · Cited by 67
Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Adiponectin alleviated Alzheimer‐like pathologies via autophagy‐lysosomal activation
He, K., Nie, L., Ali, T., Wang, S., Chen, X., Liu, Z., Li, W., Zhang, K., Xu, J., Liu, J., et al. (2021) · Aging Cell · doi:10.1111/acel.13514 · Cited by 64
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 72
Li, S., Jin, M., Liu, L., Dang, Y., Ostaszewski, B. L., & Selkoe, D. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0626-x · Cited by 64
Rahmadi, A., Steiner, N., & Münch, G. W. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.079 · Cited by 63
Erickson, C. M., Chin, N. A., Johnson, S. C., Gleason, C. E., & Clark, L. R. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12150 · Cited by 64
Almuhayawi, M. S., Ramadan, W. S., Harakeh, S., Jaouni, S. K. A., Bharali, D. J., Mousa, S. A., & Almuhayawi, S. M. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.04.045 · Cited by 64
Biochemical deficits and cognitive decline in brain aging: Intervention by dietary supplements
Poddar, J., Pradhan, M., Ganguly, G., & Chakrabarti, S. (2018) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.04.002 · Cited by 63
Synthesis of novel sulfonamides with anti‐Alzheimer and antioxidant capacities
Gök, N., Akıncıoğlu, A., Binici, E. E., Akıncıoğlu, H., Kılınç, N., & Göksu, S. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202000496 · Cited by 62
BACE1 as a Potential Biomarker for Alzheimer's Disease
Decourt, B., & Sabbagh, M. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110017 · Cited by 62
Si, G., & Álvarez, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21722 · Cited by 61
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
Giulietti, G., Bozzali, M., Figura, V., Spanò, B., Perri, R., Marra, C., Lacidogna, G., Giubilei, F., Caltagirone, C., & Cercignani, M. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.043 · Cited by 60
Scherder, E., Eggermont, L. H. P., Visscher, C., Scheltens, P., & Swaab, D. F. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.08.009 · Cited by 62
Subjective Cognitive Decline Is Associated with Greater White Matter Hyperintensity Volume
van Rooden, S., van den Berg‐Huysmans, A. A., Croll, P. H., Labadie, G., Hayes, J. M., Viviano, R. P., van der Grond, J., Rombouts, S. A. R. B., & Damoiseaux, J. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180285 · Cited by 64
Uemura, M. T., Robinson, J. L., Cousins, K. A. Q., Tropea, T. F., Kargilis, D., McBride, J. D., Suh, E. R., Xie, S. X., Xu, Y., Porta, S., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02383-3 · Cited by 59
Cognitive reserve and the risk for Alzheimer's disease: a longitudinal study
Serra, L., Musicco, M., Cercignani, M., Torso, M., Spanò, B., Mastropasqua, C., Giulietti, G., Marra, C., Bruno, G., Koch, G., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.010 · Cited by 60
Understanding Dementia Prevalence Among Centenarians
Poon, L. W., Woodard, J. L., Miller, L. S., Green, R. C., Gearing, M., Davey, A., Arnold, J., Martin, P., Siegler, I. C., Nahapetyan, L., et al. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr250 · Cited by 59
Self-citationBeta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 62
Homeostatic Disinhibition in the Aging Brain and Alzheimer's Disease
Gleichmann, M., Chow, V. W., & Mattson, M. P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101674 · Cited by 59
A comparison of three brain atlases for MCI prediction
Ota, K., Oishi, N., Ito, K., & Fukuyama, H. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.10.003 · Cited by 61
Nordberg, A. K. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt96 · Cited by 58
A 2-process model for neuropathology of Alzheimer's disease
Mungas, D., Tractenberg, R., Schneider, J. A., Crane, P. K., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.007 · Cited by 58
The Merits of FDDNP-PET Imaging in Alzheimer's Disease
Shin, J., Kepe, V., Barrio, J. R., & Small, G. W. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0008 · Cited by 62
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis
Bocancea, D. I., Svenningsson, A. L., van Loenhoud, A. C., Groot, C., Barkhof, F., Strandberg, O. T., Smith, R. A., Initiative, A. D. N., Weiner, M. W., Aisen, P., et al. (2023) · Brain · doi:10.1093/brain/awad100 · Cited by 59
Rauch, S. M., Huen, K. H. Y., Miller, M. C., Chaudry, H., Lau, M., Sanes, J. R., Johanson, C. E., Stopa, E. G., & Burgess, R. W. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31823b0b12 · Cited by 59
Behavioral and neuropsychiatric disorders in Alzheimer's disease
Cortés, N., Andrade, V., & Maccioni, R. B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180005 · Cited by 57
Neuron Specific Toxicity of Oligomeric Amyloid-β: Role for JUN-Kinase and Oxidative Stress
Ebenezer, P. J., Weidner, A. M., LeVine, H., Markesbery, W. R., Murphy, M. P., Zhang, L., Dasuri, K., Fernandez-Kim, S. O., Bruce-Keller, A. J., Gavilán, E., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101161 · Cited by 58
Self-citationLu, M., Pontecorvo, M. J., Devous, M. D., Arora, A. K., Galante, N., McGeehan, A., Devadanam, C., Salloway, S. P., Doraiswamy, P. M., Curtis, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5505 · Cited by 56
Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment
Mufson, E. J., Malek‐Ahmadi, M. H., Perez, S. E., & Chen, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.012 · Cited by 60
Alcántara-González, F., Mendoza-Perez, C. R., Zaragoza, N., Juárez, I., Arroyo‐García, L. E., Gamboa, C., de la Cruz, F., Zamudio, S., García‐Dolores, F., & Flores, G. (2012) · Synapse · doi:10.1002/syn.21588 · Cited by 56
Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain
Grear, K. E., Ling, I.-F., Simpson, J. F., Furman, J. L., Simmons, C. R., Peterson, S. L., Schmitt, F. A., Markesbery, W. R., Liu, Q., Crook, J. E., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-46 · Cited by 56
Self-citationComparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Roe, C. M., Ghoshal, N., Morris, J. C., Cairns, N. J., & Kukull, W. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d7a1 · Cited by 57
Exercise-Induced Modulation of Neuroinflammation in Models of Alzheimer’s Disease
Kelly, Á. M. (2018) · Brain Plasticity · doi:10.3233/bpl-180074 · Cited by 55
Reliable Measurements of theβ-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
Pesini, P., Pérez‐Grijalba, V., Monleón, I., Boada, M., Tárraga, L., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/604141 · Cited by 57
Metadata
- Authors
- Nelson, P. T., Braak, H., & Markesbery, W. R.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
- Corresponding author
- Nelson, Peter T.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 68
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- PMC
- PMC2692822
- OpenAlex
- W1985747467
- Cited by
- 643
- References
- 155
- Citations by year
- 2026: 21 · 2025: 43 · 2024: 48 · 2023: 46 · 2022: 33 · 2021: 45 · 2020: 44 · 2019: 33 · 2018: 32 · 2017: 32 · 2016: 37 · 2015: 32 · 2014: 35 · 2013: 42 · 2012: 41
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (AG028 383)
- National Institute on Aging (P30AG028383)
- National Institute of Neurological Disorders and Stroke (R01NS061933, K08NS050110)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid plaques, neurofibrillary tangles, cognitive impairment, clinicopathological correlation, Alzheimer's disease diagnosis, Alzheimer disease pathogenesis, autopsy findings
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, Neurofibrillary Tangles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
